Contrast agents in dynamic contrast-enhanced magnetic resonance imaging

Yuling Yan; Xilin Sun; Baozhong Shen

doi:10.18632/oncotarget.16482

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Contrast agents in dynamic contrast-enhanced magnetic resonance imaging

Yuling Yan _, Xilin Sun and Baozhong Shen

PDF | HTML | How to cite

Oncotarget. 2017; 8:43491-43505. https://doi.org/10.18632/oncotarget.16482

Metrics: PDF 2747 views | HTML 4519 views | ?

Abstract

Yuling Yan1,2, Xilin Sun1,2,3 and Baozhong Shen1,2

1 Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, China

2 TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China

3 Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, California, USA

Correspondence to:

Baozhong Shen, email:

Xilin Sun, email:

Keywords: DCE-MRI, contrast agent, macromolecular contrast agent, nanoparticle, low molecular contrast agent

Received: January 07, 2017 Accepted: March 15, 2017 Published: March 22, 2017

Abstract

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a noninvasive method to assess angiogenesis, which is widely used in clinical applications including diagnosis, monitoring therapy response and prognosis estimation in cancer patients. Contrast agents play a crucial role in DCE-MRI and should be carefully selected in order to improve accuracy in DCE-MRI examination. Over the past decades, there was much progress in the development of optimal contrast agents in DCE-MRI. In this review, we describe the recent research advances in this field and discuss properties of contrast agents, as well as their advantages and disadvantages. Finally, we discuss the research perspectives for improving this promising imaging method.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16482

Publication Alerts

Oncoscience

Post-Publication Promotion

Reviews:

Contrast agents in dynamic contrast-enhanced magnetic resonance imaging

Abstract